Kairos Pharma Reports 17.7-Month Median PFS in ENV-105 Trial

Kairos Pharma reported median progression-free survival of 17.7 months with ENV-105 plus apalutamide, versus 2 months with apalutamide alone, in a Phase 2 mCRPC trial (P=0.0008). The trial will focus on first-line therapy after enzalutamide in a larger group.